Clinical trials
Hematopoietic Cell Transplantation clinical trials
Below are recruiting hematopoietic cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 396 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+ - NCT03665675RecruitingEarly Phase 1
Immune cell treatment to control CMV or adenovirus after transplant
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Columbus, OhioAges 1–85 - NCT07304232RecruitingPhase 2
Chidamide after stem cell transplant for AML
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
Shijiazhuang, HebeiAges 18–75 - NCT07709195RecruitingPhase 2
Chlorophyllin to reduce mouth sores from radiation before transplant
This trial tests whether taking chlorophyllin can reduce mouth sores caused by total body radiation given before a stem cell transplant. The goal is to make the treatment easier to tolerate.
Navi Mumbai, MaharashtraAges 12–65 - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT07777406Recruiting
Real-world study of donor stem cell transplant for relapsed/refractory myeloma
This study looks at real-world outcomes in patients who have had a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to gather info on how well this approach works in everyday practice.
Chieti, CHAges 18 years+ - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07105579RecruitingPhase 2
Blinatumomab and donor cells after transplant for high-risk B-ALL
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
HangzhouAges 14–65 - NCT04836390Enrolling by invitationPhase 2
Donor immune cell treatment after transplant for high-risk AML
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Phoenix, ArizonaAges birth–25 years - NCT00736749Recruiting
Long-term health check for childhood cancer survivors
This trial tracks the long-term health of people who took part in previous Children's Oncology Group studies. It helps doctors understand the lasting effects of cancer treatment and improve care for survivors.
Birmingham, AlabamaAges Any age - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT05508009RecruitingPhase 1/Phase 2
Kidney transplant with donor-matched stem cell treatment
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
Palo Alto, CaliforniaAges 1–30 - NCT07845942Recruiting
Donor stem cell transplant for stubborn systemic juvenile arthritis
This study tests a bone marrow transplant (using donor cells) to treat severe systemic juvenile idiopathic arthritis (sJIA) that has not responded to other treatments. The goal is to reset the immune system to stop the disease and its complications, like lung problems or recurrent macrophage activation syndrome.
Cincinnati, OhioAges Up to 35 years - NCT07586735Recruiting
A new preparative regimen for stem cell transplant in older patients with severe aplastic anemia
This study tests a new combination of drugs to prepare older patients (40–60 years old) with severe aplastic anemia for a stem cell transplant from a half-matched donor. The goal is to make the transplant safer and more effective for this age group.
Beijing, Beijing MunicipalityAges 40–60 - NCT07463651RecruitingPhase 3
Gilteritini vs Sorafenib after transplant for FLT3-ITD AML
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Suzhou, JiangsuAges 14–70 - NCT07308457Recruiting
Comparing infection monitoring vs. antibiotic prevention in stem cell transplant
This trial compares two ways to prevent infections after a stem cell transplant: using a standard antibiotic (ceftriaxone) or closely watching for germs in the blood and treating only if needed. It aims to find which method is safer and more effective for people receiving a stem cell transplant.
Szczecin, West Pomeranian VoivodeshipAges 18 years+ - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT07305090Recruiting
Gut GVHD biomarker study for transplant patients
This trial aims to develop a test using multiple biomarkers to predict how well patients will respond to treatment for acute graft-versus-host disease (GVHD) affecting the gut. It focuses on patients who are receiving an allogeneic stem cell transplant.
Bologna, BolognaAges 12 years+ - NCT07104799RecruitingPhase 1
Momelotinib before and after stem cell transplant for myelofibrosis
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
Boston, MassachusettsAges 18 years+ - NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT06646640Recruiting
Long-term follow-up for hemoglobin disorder treatments
This study tracks people with sickle cell disease or thalassemia who have had a bone marrow transplant or gene therapy in the past 15 years. It aims to monitor their health over time to understand long-term effects.
Memphis, TennesseeAges Any age - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06498973RecruitingPhase 1
Maintenance therapy after stem cell transplant for CD123-positive AML/MDS
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
Duarte, CaliforniaAges 18–75
Hear when a new Hematopoietic Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematopoietic cell transplantation?
- Yes. Clin2 currently lists 396 recruiting hematopoietic cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematopoietic cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematopoietic cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
- Clear Cell Renal Cell Carcinoma
- Hematopoietic and Lymphoid Cell Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.